Clinical trials: Hospitalized COVID-19
Covid-19
Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19
The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19.
- Trial name
- NCT04724720
- Testing
- Famotidine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Northwell Health
Telemedicine, Epidemic Disease
Early Transfer of Hospitalized Patients Incl. COVID-19 to a Virtual Hospital at Home Model - a Clinical Feasibility Study
This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission.
- Trial name
- Influenz-er (NCT05087082)
- Testing
- Virtual Hospital at Home - Home admission of epidemic patients
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Nordsjaellands Hospital
COVID-19, Acute Kidney Injury
Acute Kidney Injury in Patients Hospitalized With COVID-19
The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.
- Conditions
- COVID-19, Acute Kidney Injury, Kidney Function
- Trial name
- NCT04316299
- Where
- China
- Volunteers
- 287 people
- Sponsor
- Zhenhua Zen
SARS CoV 2 Infection, COVID-19
I VACCIN Hospitalization of COVID-19 Patients
A REALLIFE evaluation of rate of hospitalized patients in Intensive Care Units and in medical Units of non -vaccinated patients vs vaccinated patients
- Trial name
- NCT05244343
- Where
- Tunisia
- Volunteers
- 1,096 people
- Sponsor
- Eshmoun Clinical Research Center
COVID-19
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19
This is a multicenter double blinded study to evaluate the efficacy and safety of convalescent plasma from COVID-19 recovered individuals to treat hospitalized patients with severe COVID-19 disease.
- Trial name
- EPCOvid-1 (NCT04388410)
- Testing
- convalescent plasma
- Where
- Mexico
- Volunteers
- 410 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
COVID-19, Influenza
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza…
- Trial name
- DAN-COMBO (NCT07790523)
- Testing
- mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- Where
- 3 sites in Denmark, Spain
- Volunteers
- 410,000 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
COVID19
FAvipiravir and HydroxyChloroquine Combination Therapy
This study is a randomized, open-label, parallel groups multi-centered trial were participants are assigned to either an intervention arm ( a combination of Favipiravir and Hydroxychloroquin) or standard of care.
- Trial name
- FACCT (NCT04392973)
- Testing
- Favipiravir and Hydroxychloroquine
- Where
- 8 sites in Saudi Arabia
- Volunteers
- 268 people
- Sponsor
- King Abdullah International Medical Research Center
COVID-19
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement…
- Trial name
- COLCOVID (NCT04328480)
- Testing
- Colchicine, Local standard of care
- Where
- Argentina
- Volunteers
- 1,279 people
- Sponsor
- Estudios Clínicos Latino América
Pneumonia, Viral, COVID-19
Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19
Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies. The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency…
- Trial name
- NCT04341766
- Testing
- No special intervention
- Where
- 17 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Pulmonary Thromboembolism
Thromboembolic Events in Severe COVID-19 Patients
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19.
- Trial name
- COVICLOT (NCT04405869)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Coronavirus Disease 2019
Clinical Outcomes of Patients With COVID19
As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of…
- Trial name
- NCT04280913
- Testing
- retrospective analysis
- Where
- China
- Sponsor
- Guangzhou Institute of Respiratory Disease
Diabetes Mellitus, COVID-19
Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)
Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after…
- Conditions
- Diabetes Mellitus, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- DMD-COV (NCT07560059)
- Testing
- No intervention (observational study)
- Where
- Algeria
- Volunteers
- 201 people
- Sponsor
- Algerian Society of Diabetology
SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)
Methylprednisolone in COVID-19 Patients (Methyl19LGH)
In COVID-19 deep airway and alveolar destruction occurred due to inflammatory reaction resulting into severe pneumonia. In COVID-19, lung injury is not only due to viral damage to tissue, but it is also due to immune response…
- Trial name
- Methyl19LGH (NCT04559113)
- Testing
- Methylprednisolone Injectable Product
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Lahore General Hospital
Covid19
SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)
SOLIDARITY Finland Long-COVID trial assesses the effects of remdesivir + standard of care (SoC) vs. only SoC on long-COVID symptoms and quality of life (QoL) using questionnaires at one and two years post-discharge.
- Trial name
- NCT04978259
- Testing
- Remdesivir
- Where
- Finland
- Volunteers
- 202 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
COVID19 Patients
Support for COVID19 Patients at Home
The rapid spread and increase of acute respiratory infection cases caused by the novel SARS-CoV-2 coronavirus represent a major challenge for healthcare systems around the world.
- Trial name
- Mirato (NCT04898179)
- Testing
- Telecare Group, Control group
- Where
- 4 sites in Italy
- Volunteers
- 796 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
COVID-19 Pneumonia
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.
Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade.
- Trial name
- NCT05118737
- Testing
- Colchicine
- Where
- Qatar
- Volunteers
- 230 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of tofacitinib in hospitalized adult participants with COVID-19 pneumonia who are receiving SoC…
- Trial name
- NCT04412252
- Testing
- Tofacitinib
- Where
- 6 sites in United States
- Sponsor
- Pfizer